Abeona Therapeutics added to membership of Russell 2000, Russell 3000

Abeona Therapeutics (ABEO) announced that it was added as a member of the U.S. small-cap Russell 2000 Index and the broad-market Russell 3000 Index as part of the reconstitution of the Russell stock indexes, effective at the open of the U.S. equity markets. “Abeona’s addition to the Russell 2000 and 3000 indexes, on the heels of ZEVASKYN(TM)’s FDA approval, represents a pivotal moment for the company,” said Joe Vazzano, Chief Financial Officer of Abeona. “This inclusion amplifies our positive momentum as we progress with ZEVASKYN’s commercial launch and provides an opportunity to engage with a broader audience of investors.”